<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.1210/jendso/bvaa082bvaa082 : Mini-Reviews: AcademicSubjects/MED00250 The Impact of SARS-Cov-2 Virus" exact="Infection" post="on the Endocrine System http://orcid.org/0000-0002-6241-7501SomasundaramNoel Pratheepan1noelsomasundaram@gmail.comhttp://orcid.org/0000-0002-2188-5309RanathungaIshara1RatnasamyVithiya2WijewickramaPiyumi Sachindra Alwis1DissanayakeHarsha Anuruddhika2YogendranathanNilukshana2GamageKavinga"/>
 <result pre="http://orcid.org/0000-0002-6241-7501SomasundaramNoel Pratheepan1noelsomasundaram@gmail.comhttp://orcid.org/0000-0002-2188-5309RanathungaIshara1RatnasamyVithiya2WijewickramaPiyumi Sachindra Alwis1DissanayakeHarsha Anuruddhika2YogendranathanNilukshana2GamageKavinga Kalhari Kobawaka1de SilvaNipun Lakshitha13SumanatillekeManilka1KatulandaPrasad24GrossmanAshley Barry56[1]," exact="Diabetes" post="and Endocrine Unit, National Hospital of Sri LankaSri Lanka[2],"/>
 <result pre="Sri LankaSri Lanka[3], Department of Clinical Sciences, Faculty of Medicine," exact="General" post="Sir John Kotelawala Defence UniversitySri Lanka[4], Diabetes Research Unit,"/>
 <result pre="Faculty of Medicine, General Sir John Kotelawala Defence UniversitySri Lanka[4]," exact="Diabetes" post="Research Unit, Department of Clinical Medicine, Faculty of Medicine,"/>
 <result pre="School of Medicine, Queen Mary University of LondonUK Correspondence:â€ƒN.P. Somasundaram," exact="Diabetes" post="and Endocrine Unit, National Hospital of Sri Lanka, Colombo"/>
 <result pre="properly cited. For commercial re-use, please contact journals.permissions@oup.combvaa082.pdf Abstract Abstract" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has spread"/>
 <result pre="cited. For commercial re-use, please contact journals.permissions@oup.combvaa082.pdf Abstract Abstract Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has spread across"/>
 <result pre="For commercial re-use, please contact journals.permissions@oup.combvaa082.pdf Abstract Abstract Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) virus has spread across the"/>
 <result pre="commercial re-use, please contact journals.permissions@oup.combvaa082.pdf Abstract Abstract Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) virus has spread across the globe"/>
 <result pre="management decisions. Hydrocortisone dose adjustments are required in patients with" exact="adrenal insufficiency." post="Identification and management of critical illness-related corticosteroid insufficiency is"/>
 <result pre="management of critical illness-related corticosteroid insufficiency is crucial. Patients with" exact="Cushing" post="syndrome may have poorer outcomes because of the associated"/>
 <result pre="of critical illness-related corticosteroid insufficiency is crucial. Patients with Cushing" exact="syndrome" post="may have poorer outcomes because of the associated immunodeficiency"/>
 <result pre="Cushing syndrome may have poorer outcomes because of the associated" exact="immunodeficiency" post="and coagulopathy. Vitamin D deficiency appears to be associated"/>
 <result pre="outcomes because of the associated immunodeficiency and coagulopathy. Vitamin D" exact="deficiency" post="appears to be associated with increased susceptibility or severity"/>
 <result pre="discussed extensively in this mini-review. SARS-CoV2 COVID-19 Endocrine page-count: Coronavirus" exact="disease" post="2019 (COVID-19), which was first reported in Wuhan, Hubei"/>
 <result pre="major pandemic [1]. It is caused by the virus severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus that"/>
 <result pre="pandemic [1]. It is caused by the virus severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus that is"/>
 <result pre="[1]. It is caused by the virus severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the seventh coronavirus that is known"/>
 <result pre="2 (SARS-CoV-2), the seventh coronavirus that is known to cause" exact="disease" post="in humans [2]. Within 6 months, the number of"/>
 <result pre="in our time [3]. Because SARS-CoV-2 is a novel virus," exact="limited" post="data are available on the effect of the virus"/>
 <result pre="SARS-CoV-1, studying the pathogenesis and clinical impact of the known" exact="disease" post="should be helpful in understanding the possible effects of"/>
 <result pre="be helpful in understanding the possible effects of the novel" exact="disease" post="[4]. 1. Pathogenesis SARS-CoV-1 and SARS-CoV-2 belong to the"/>
 <result pre="angiotensin-converting enzyme 2 (ACE2) as the receptor for fusion of" exact="viral" post="and host membranes [7â€&quot;9]. It appears that SARS-CoV-2 also"/>
 <result pre="attachment [5, 10, 11]. The inhaled virus binds to the" exact="epithelial" post="cells of the nasal cavity [12]. Ciliated cells in"/>
 <result pre="cavity [12]. Ciliated cells in the conducting airway are the" exact="primary" post="cells where the virus binds. In this initial phase,"/>
 <result pre="ACE2 expression is highest in kidney, endothelium, lungs, and the" exact="heart" post="[13, 16]. The main substrate for ACE2 is angiotensin"/>
 <result pre="is in a metastable prefusion state. The S1 subunit triggers" exact="viral" post="envelope fusion with the cell membrane via the endosomal"/>
 <result pre="from the prefusion conformation and allows S2 to attain a" exact="stable" post="postfusion state [19â€&quot;21]. The cleavage of S protein of"/>
 <result pre="and clathrin-independent endocytosis may also be involved in mediating the" exact="viral" post="entry [23, 24]. Following cellular entry, the virus then"/>
 <result pre="genome RNA into the host cell which get translated into" exact="viral" post="replicase polyproteins pp1a and 1ab [25]. These proteins are"/>
 <result pre="[25]. These proteins are further cleaved into small particles by" exact="viral" post="proteinases. The polymerase produces more subgenomic mRNAs in a"/>
 <result pre="a serial manner that are ultimately translated into the relevant" exact="viral" post="proteins that are assembled in the endoplasmic reticulum and"/>
 <result pre="sufficient evidence in favor of ACE2 as the mediator of" exact="viral" post="entry into alveolar cells, and local harmful activation of"/>
 <result pre="is being considered as a serious therapeutic option. Figure 1." exact="Viral" post="entry and cellular pathogenesis. The SARS-CoV-2 virus enters the"/>
 <result pre="Viral entry and cellular pathogenesis. The SARS-CoV-2 virus enters the" exact="respiratory" post="tract via the epithelial cells in the nasal cavity"/>
 <result pre="pathogenesis. The SARS-CoV-2 virus enters the respiratory tract via the" exact="epithelial" post="cells in the nasal cavity (1). The virus binds"/>
 <result pre="2 subunits (3). The S1 subunit promotes fusion of the" exact="viral" post="envelope with the host cell membrane culminating endocytosis of"/>
 <result pre="releases its genomic RNA into the host cell (5). The" exact="viral" post="RNA is translated into polyproteins pp1a and 1ab, both"/>
 <result pre="genomic RNA gets transcribed into mRNA (7) and results in" exact="viral" post="protein synthesis via translation (8). The replicated genomic RNA"/>
 <result pre="via translation (8). The replicated genomic RNA and the synthesized" exact="viral" post="proteins are incorporated into virions in the RER and"/>
 <result pre="host cell as vesicles via exocytosis (10). pp1a and 1ab," exact="viral" post="replicase polyproteins; RER, rough endoplasmic reticulum; S, Spike protein;"/>
 <result pre="Spike protein; TMPRSS2, transmembrane protease serine 2. Following the initial" exact="symptomatic" post="period without a significant immune response, the second phase"/>
 <result pre="Following entry of the virus into the host cells, the" exact="viral" post="antigens are presented by antigen-presenting cells recognized by cytotoxic"/>
 <result pre="polymorphisms are related to the susceptibility and protection from SARS-CoV-1" exact="infection" post="[30â€&quot;32]. Both cellular and humoral immunity are subsequently activated"/>
 <result pre="patients [33, 34]. The potentially life-threatening complication of coronavirus is" exact="acute" post="respiratory distress syndrome (ARDS), which is secondary to a"/>
 <result pre="[33, 34]. The potentially life-threatening complication of coronavirus is acute" exact="respiratory" post="distress syndrome (ARDS), which is secondary to a â€œcytokine"/>
 <result pre="The potentially life-threatening complication of coronavirus is acute respiratory distress" exact="syndrome" post="(ARDS), which is secondary to a â€œcytokine stormâ€� induced"/>
 <result pre="of coronavirus is acute respiratory distress syndrome (ARDS), which is" exact="secondary" post="to a â€œcytokine stormâ€� induced by the hyperactivation of"/>
 <result pre="stimulating factor, granulocyte macrophage colony stimulating factor, interferon-Î³ (IFN-Î³), TNF-Î±," exact="monocyte" post="chemoattractant protein-1 (MCP1), macrophage inflammatory protein Î±, and vascular"/>
 <result pre="TNF-Î±, monocyte chemoattractant protein-1 (MCP1), macrophage inflammatory protein Î±, and" exact="vascular" post="endothelial growth factor-A have been reported in those with"/>
 <result pre="body via the nasal passage may gain access to the" exact="central nervous system" post="via the olfactory bulb through synapses as in SARS-CoV-1"/>
 <result pre="olfactory bulb through synapses as in SARS-CoV-1 and Middle East" exact="respiratory" post="syndrome-coronavirus (MERS-CoV) [38, 39], and this may also be"/>
 <result pre="symptoms of loss of taste and smell. Involvement of the" exact="brain" post="has been reported in patients with severe COVID-19 [40]."/>
 <result pre="[40]. There is also evidence that SARS-CoV-2 causes significant cardiac" exact="and renal disease," post="possibly from ACE2/renin-angiotensin system-related impact. 2. Pituitary SARS-CoV-1 has"/>
 <result pre="There is also evidence that SARS-CoV-2 causes significant cardiac and" exact="renal disease," post="possibly from ACE2/renin-angiotensin system-related impact. 2. Pituitary SARS-CoV-1 has"/>
 <result pre="cardiac and renal disease, possibly from ACE2/renin-angiotensin system-related impact. 2." exact="Pituitary" post="SARS-CoV-1 has been known to affect the hypothalamo-pituitary-adrenal axis"/>
 <result pre="has been known to affect the hypothalamo-pituitary-adrenal axis (HPA) causing" exact="transient" post="hypocortisolism. Less commonly, the hypothalamo-pituitary-thyroid axis is affected leading"/>
 <result pre="hypocortisolism. Less commonly, the hypothalamo-pituitary-thyroid axis is affected leading to" exact="secondary" post="hypothyroidism [41]. Both reversible hypophysitis and a direct hypothalamic"/>
 <result pre="Less commonly, the hypothalamo-pituitary-thyroid axis is affected leading to secondary" exact="hypothyroidism" post="[41]. Both reversible hypophysitis and a direct hypothalamic effect"/>
 <result pre="have been reported as possible mechanisms [41]. In SARS-CoV-1 survivors," exact="hypocortisolism" post="has been reported to develop gradually as a late"/>
 <result pre="complication over a number of weeks from the onset of" exact="infection" post="[41]. Postviral syndromes manifest as low energy levels, low"/>
 <result pre="dizziness; these have been shown to be associated with postviral" exact="hypocortisolism" post="and are dramatically improved with cortisol replacement [41]. Furthermore,"/>
 <result pre="for ACE receptors are associated with an increased risk of" exact="idiopathic chronic fatigue" post="and chronic fatigue syndrome [42]. These effects have been"/>
 <result pre="ACE receptors are associated with an increased risk of idiopathic" exact="chronic" post="fatigue and chronic fatigue syndrome [42]. These effects have"/>
 <result pre="associated with an increased risk of idiopathic chronic fatigue and" exact="chronic fatigue syndrome" post="[42]. These effects have been suggested to be mediated"/>
 <result pre="an increased risk of idiopathic chronic fatigue and chronic fatigue" exact="syndrome" post="[42]. These effects have been suggested to be mediated"/>
 <result pre="it may play a role in postviral fatigue and associated" exact="hypocortisolism" post="[43, 44]. It has been demonstrated that SARS-CoV enters"/>
 <result pre="[43, 44]. It has been demonstrated that SARS-CoV enters the" exact="brain" post="via an ACE2 receptor located in the olfactory bulb"/>
 <result pre="mimicry with ACTH; this would lead to host antibodies against" exact="viral" post="antigens binding to ACTH receptors, limiting the corticosteroid stress"/>
 <result pre="receptors, limiting the corticosteroid stress response [46]. Patients who developed" exact="hypocortisolism" post="were found to recover their HPA axis within 1"/>
 <result pre="to occur in response to any form of stress, including" exact="infections" post="[48]. High prolactin levels have been shown in patients"/>
 <result pre="in patients with severe sepsis and in infants with severe" exact="respiratory" post="infections [49, 50]. Prolactin also has shown immunomodulatory and"/>
 <result pre="patients with severe sepsis and in infants with severe respiratory" exact="infections" post="[49, 50]. Prolactin also has shown immunomodulatory and anti-inflammatory"/>
 <result pre="in experimental studies [51]. However, no data are available on" exact="susceptibility to" post="infection among patients with hyperprolactinemia or any risk conferred"/>
 <result pre="studies [51]. However, no data are available on susceptibility to" exact="infection" post="among patients with hyperprolactinemia or any risk conferred by"/>
 <result pre="data are available on susceptibility to infection among patients with" exact="hyperprolactinemia" post="or any risk conferred by prolactin-lowering therapy. Table 1"/>
 <result pre="Effect on Hormonal Axis Clinical Features Management Issues and Solutions" exact="Pituitary" post="Central hypocortisolism and hypothyroidism Hypophysitis resulting from infiltration by"/>
 <result pre="on Hormonal Axis Clinical Features Management Issues and Solutions Pituitary" exact="Central" post="hypocortisolism and hypothyroidism Hypophysitis resulting from infiltration by virus"/>
 <result pre="Hormonal Axis Clinical Features Management Issues and Solutions Pituitary Central" exact="hypocortisolism" post="and hypothyroidism Hypophysitis resulting from infiltration by virus [41]"/>
 <result pre="Clinical Features Management Issues and Solutions Pituitary Central hypocortisolism and" exact="hypothyroidism" post="Hypophysitis resulting from infiltration by virus [41] Hypothalamic involvement"/>
 <result pre="replacement in physiological doses [41] Hyperprolactinemia Dopaminergic stress response [48]" exact="Transient" post="hyperprolactinemia Asymptomatic Prolactin levels may be high during acute"/>
 <result pre="in physiological doses [41] Hyperprolactinemia Dopaminergic stress response [48] Transient" exact="hyperprolactinemia" post="Asymptomatic Prolactin levels may be high during acute illness."/>
 <result pre="[48] Transient hyperprolactinemia Asymptomatic Prolactin levels may be high during" exact="acute" post="illness. Caution on interactions of DRA with CYP450 inducing"/>
 <result pre="by degradation of ACE2 [53, 54] Hypokalemia Clinical features of" exact="hypokalemia" post="Monitor electrolytes Replacement Adrenal Hypoadrenalism Adrenal necrosis and vasculitis"/>
 <result pre="[53, 54] Hypokalemia Clinical features of hypokalemia Monitor electrolytes Replacement" exact="Adrenal" post="Hypoadrenalism Adrenal necrosis and vasculitis from direct cytopathic effect"/>
 <result pre="Hypokalemia Clinical features of hypokalemia Monitor electrolytes Replacement Adrenal Hypoadrenalism" exact="Adrenal" post="necrosis and vasculitis from direct cytopathic effect or inflammatory"/>
 <result pre="of hypokalemia Monitor electrolytes Replacement Adrenal Hypoadrenalism Adrenal necrosis and" exact="vasculitis" post="from direct cytopathic effect or inflammatory response [29, 59]"/>
 <result pre="vasculitis from direct cytopathic effect or inflammatory response [29, 59]" exact="Hypocortisolism" post="Postural hypotension Persistently low blood pressure Hyperkalemia and hyponatremia"/>
 <result pre="59] Hypocortisolism Postural hypotension Persistently low blood pressure Hyperkalemia and" exact="hyponatremia" post="Serum 9 am cortisol Cosyntropin test Hydrocortisone therapy Thyroid"/>
 <result pre="and hyponatremia Serum 9 am cortisol Cosyntropin test Hydrocortisone therapy" exact="Thyroid" post="Hypothyroidism Destruction of follicular and parafollicular cells of thyroid"/>
 <result pre="hyponatremia Serum 9 am cortisol Cosyntropin test Hydrocortisone therapy Thyroid" exact="Hypothyroidism" post="Destruction of follicular and parafollicular cells of thyroid [83]"/>
 <result pre="Hypothyroidism Destruction of follicular and parafollicular cells of thyroid [83]" exact="Primary" post="hypothyroidism Hypothyroid features High TSH and low free T4"/>
 <result pre="Destruction of follicular and parafollicular cells of thyroid [83] Primary" exact="hypothyroidism" post="Hypothyroid features High TSH and low free T4 Thyroxine"/>
 <result pre="TSH and low free T4 Thyroxine replacement Decreased activity of" exact="type 1" post="deiodinase activity, increased activity of type 3 deiodinase activity,"/>
 <result pre="Decreased activity of type 1 deiodinase activity, increased activity of" exact="type 3" post="deiodinase activity, and down-regulation of hypothalamic pituitary axis [82]"/>
 <result pre="[82] Sick euthyroidism Clinically not significant Difficulty in differentiating during" exact="acute" post="illness, test TSH and free T4 following recovery Hypophysitis/"/>
 <result pre="TSH and free T4 following recovery Hypophysitis/ hypothalamic involvement [41]" exact="Central" post="hypothyroidism Hypothyroid features Low TSH and free T4 Thyroxine"/>
 <result pre="and free T4 following recovery Hypophysitis/ hypothalamic involvement [41] Central" exact="hypothyroidism" post="Hypothyroid features Low TSH and free T4 Thyroxine replacement"/>
 <result pre="Low TSH and free T4 Thyroxine replacement Pancreas Hypo-/hyperglycemia Direct" exact="viral" post="injury on ACE2 expressing islet cells [89] Hyperglycemia glycosylates"/>
 <result pre="on ACE2 expressing islet cells [89] Hyperglycemia glycosylates ACE2 and" exact="viral" post="S protein, facilitating viral entry [92] Pancreatitis [90]: direct"/>
 <result pre="cells [89] Hyperglycemia glycosylates ACE2 and viral S protein, facilitating" exact="viral" post="entry [92] Pancreatitis [90]: direct viral injury, response to"/>
 <result pre="viral S protein, facilitating viral entry [92] Pancreatitis [90]: direct" exact="viral" post="injury, response to systemic inflammation, immune-mediated injury Possible hypoinsulinemia"/>
 <result pre="viral entry [92] Pancreatitis [90]: direct viral injury, response to" exact="systemic" post="inflammation, immune-mediated injury Possible hypoinsulinemia Stress response up-regulates cortisol,"/>
 <result pre="titration of treatment Potential anti-COVID therapies may cause hypo- and" exact="hyperglycemia" post="[100] Parathyroid No direct effect Not identified Not identified"/>
 <result pre="treatment Potential anti-COVID therapies may cause hypo- and hyperglycemia [100]" exact="Parathyroid" post="No direct effect Not identified Not identified None Gonads"/>
 <result pre="Parathyroid No direct effect Not identified Not identified None Gonads" exact="Hypogonadism" post="Entry of virus into spermatogonia and somatic cells using"/>
 <result pre="124] Destruction of seminiferous tubules and reduced spermatozoa from immune-mediated" exact="orchitis" post="[126] Impaired spermatogenesis and androgen synthesis Male hypogonadism and"/>
 <result pre="from immune-mediated orchitis [126] Impaired spermatogenesis and androgen synthesis Male" exact="hypogonadism" post="and subfertility Follow-up after recovery from acute infection A."/>
 <result pre="androgen synthesis Male hypogonadism and subfertility Follow-up after recovery from" exact="acute" post="infection A. Management Considerations in Patients with Preexisting (or"/>
 <result pre="synthesis Male hypogonadism and subfertility Follow-up after recovery from acute" exact="infection" post="A. Management Considerations in Patients with Preexisting (or Known)"/>
 <result pre="infection A. Management Considerations in Patients with Preexisting (or Known)" exact="Pituitary" post="Conditions Electrolyte and water imbalances can occur in COVID-19"/>
 <result pre="Endocrine Conditions who are Affected with COVID-19 Endocrine Condition Management" exact="Diabetes" post="insipidus Titrate the dose of desmopressin according to serum"/>
 <result pre="bromocriptine levels [55] Cabergoline: dose adjustment is not required GH" exact="deficiency" post="Continue on the same dose of growth hormone in"/>
 <result pre="same dose of growth hormone in those with established GH" exact="deficiency" post="[58] Hypoadrenalism Double the morning dose of hydrocortisone and"/>
 <result pre="doubled usual hydrocortisone dose (â€œsick day ruleâ€�), depending on the" exact="infection" post="severity and patient characteristics [64] During an adrenal crisis,"/>
 <result pre="on the infection severity and patient characteristics [64] During an" exact="adrenal crisis," post="IM or IV hydrocortisone 100 mg stat followed by"/>
 <result pre="followed by 200 mg over 24-hour infusion [66] Patients with" exact="primary" post="hypoadrenalism do not require increasing fludrocortisone dose [65] Critical"/>
 <result pre="by 200 mg over 24-hour infusion [66] Patients with primary" exact="hypoadrenalism" post="do not require increasing fludrocortisone dose [65] Critical illness-related"/>
 <result pre="3 days or longer depending on the requirement [70] Cushingâ€™s" exact="syndrome" post="Continue medical management in those with active disease IV"/>
 <result pre="[70] Cushingâ€™s syndrome Continue medical management in those with active" exact="disease" post="IV etomidate at a rate of 0.04 to 0.05"/>
 <result pre="level 500-800 nmol/L [78, 79] Anticoagulation to be considered in" exact="acute" post="illness [75] Pheochromocytoma/paraganglioma Treatment with initial alpha-adrenoceptor blockers followed"/>
 <result pre="blockers followed by beta-adrenoceptor blockers depending on the blood pressure" exact="and heart" post="rate [81] Hypothyroidism No thyroxine dose adjustments are required"/>
 <result pre="followed by beta-adrenoceptor blockers depending on the blood pressure and" exact="heart" post="rate [81] Hypothyroidism No thyroxine dose adjustments are required"/>
 <result pre="blockers depending on the blood pressure and heart rate [81]" exact="Hypothyroidism" post="No thyroxine dose adjustments are required Hyperthyroidism Dose adjustment"/>
 <result pre="heart rate [81] Hypothyroidism No thyroxine dose adjustments are required" exact="Hyperthyroidism" post="Dose adjustment of antithyroid medications as usual according to"/>
 <result pre="examination. Short-term block and replacement therapy as an alternative [87]" exact="Hypoparathyroidism" post="Ensure a continuous supply of calcium supplements Maintain normocalcemia"/>
 <result pre="Ensure a continuous supply of calcium supplements Maintain normocalcemia as" exact="hypocalcemia" post="increases the risk of QT prolongation with chloroquine/hydroxychloroquine and"/>
 <result pre="of QT prolongation with chloroquine/hydroxychloroquine and azithromycin [112] Vitamin D" exact="deficiency" post="Vitamin D supplements to achieve a target level ofâ€…&amp;gt;â€…50"/>
 <result pre="to 10 000 IU depending on the requirement [131, 132]" exact="Hypogonadism" post="Testosterone Temporary discontinuation may be possible if medication is"/>
 <result pre="gel) Estrogen Conversion to transdermal formulations when applicable as the" exact="thrombosis" post="risk is lower with transdermal compared to oral estrogen"/>
 <result pre="to transdermal formulations when applicable as the thrombosis risk is" exact="lower" post="with transdermal compared to oral estrogen Based on the"/>
 <result pre="estrogen Based on the currently available evidence, patients with preexisting" exact="hyperprolactinemia" post="may continue dopamine receptor agonist (DRA) therapy during the"/>
 <result pre="dopamine receptor agonist (DRA) therapy during the pandemic and during" exact="acute" post="mild to moderate COVID-19. In patients with hyperprolactinemia, prolactin"/>
 <result pre="with hyperprolactinemia, prolactin levels should not be measured to assess" exact="disease" post="control during acute illness. It is noteworthy that patients"/>
 <result pre="levels should not be measured to assess disease control during" exact="acute" post="illness. It is noteworthy that patients on DRAs who"/>
 <result pre="critically ill COVID-19 patients who require pressor support because of" exact="septic shock," post="use of amine derivatives (norepinephrine, epinephrine, dobutamine, dopamine) with"/>
 <result pre="withheld in a GH-deficient patient who develops COVID-19 [58]. 3." exact="Adrenal" post="Autopsy studies during the SARS epidemic revealed adrenal necrosis,"/>
 <result pre="Adrenal Autopsy studies during the SARS epidemic revealed adrenal necrosis," exact="vasculitis" post="of small veins of adrenal medulla, and adrenal infiltration"/>
 <result pre="monocytes and lymphocytes that was caused by SARS-CoV-1 [29, 59]." exact="Viral" post="antigens and the genomic sequence of SARS-CoV-1 were demonstrated"/>
 <result pre="and further studies. 4. Management Considerations A. COVID-19 and Preexisting" exact="Adrenal" post="Insufficiency Patients with preexisting primary or secondary adrenal insufficiency"/>
 <result pre="further studies. 4. Management Considerations A. COVID-19 and Preexisting Adrenal" exact="Insufficiency" post="Patients with preexisting primary or secondary adrenal insufficiency are"/>
 <result pre="Considerations A. COVID-19 and Preexisting Adrenal Insufficiency Patients with preexisting" exact="primary" post="or secondary adrenal insufficiency are at high risk of"/>
 <result pre="COVID-19 and Preexisting Adrenal Insufficiency Patients with preexisting primary or" exact="secondary" post="adrenal insufficiency are at high risk of complications during"/>
 <result pre="and Preexisting Adrenal Insufficiency Patients with preexisting primary or secondary" exact="adrenal insufficiency" post="are at high risk of complications during COVID-19 pandemic"/>
 <result pre="are at increased risk of mortality as a result of" exact="infections" post="triggering an adrenal crisis. Further, they are at high"/>
 <result pre="risk of mortality as a result of infections triggering an" exact="adrenal crisis." post="Further, they are at high risk of infections, particularly"/>
 <result pre="they are at high risk of infections, particularly involving the" exact="lower" post="respiratory tract, partly from impairment of natural killer cell"/>
 <result pre="are at high risk of infections, particularly involving the lower" exact="respiratory" post="tract, partly from impairment of natural killer cell function"/>
 <result pre="partly from impairment of natural killer cell function [60]. Because" exact="upper" post="respiratory tract infections are found to be the most"/>
 <result pre="from impairment of natural killer cell function [60]. Because upper" exact="respiratory" post="tract infections are found to be the most common"/>
 <result pre="of natural killer cell function [60]. Because upper respiratory tract" exact="infections" post="are found to be the most common precipitating event"/>
 <result pre="be the most common precipitating event for adrenal crises, stringent" exact="infection" post="prevention measures are recommended [61]. These patients would be"/>
 <result pre="â€œsick day rules,â€� in the event of mild to moderate" exact="infection" post="[62]. However, based on the experiences during the COVID-19"/>
 <result pre="COVID-19 pandemic, which is associated with continuous high levels of" exact="acute" post="inflammation, it is suggested that this regimen might be"/>
 <result pre="be inadequate because it can result in periods of glucocorticoid" exact="deficiency" post="in these patients with ongoing continuous inflammation [63, 64]."/>
 <result pre="recommended, based on the patient characteristics and severity of the" exact="infection" post="because it is evident that all patients with COVID-19"/>
 <result pre="to the steroid replacement dose of a COVID-19 patient with" exact="adrenal insufficiency." post="If hospitalized with pneumonia, patients should be closely monitored"/>
 <result pre="with pneumonia, patients should be closely monitored for features of" exact="acute" post="adrenal insufficiency such as syncope, vomiting, hypotension, and electrolyte"/>
 <result pre="pneumonia, patients should be closely monitored for features of acute" exact="adrenal insufficiency" post="such as syncope, vomiting, hypotension, and electrolyte imbalances including"/>
 <result pre="syncope, vomiting, hypotension, and electrolyte imbalances including hyperkalemia, hyponatremia, and" exact="hypoglycemia" post="[65]. Severe pneumonia or any features of acute adrenal"/>
 <result pre="hypotension, and electrolyte imbalances including hyperkalemia, hyponatremia, and hypoglycemia [65]." exact="Severe" post="pneumonia or any features of acute adrenal insufficiency would"/>
 <result pre="and electrolyte imbalances including hyperkalemia, hyponatremia, and hypoglycemia [65]. Severe" exact="pneumonia" post="or any features of acute adrenal insufficiency would warrant"/>
 <result pre="hyponatremia, and hypoglycemia [65]. Severe pneumonia or any features of" exact="acute" post="adrenal insufficiency would warrant IV or IM hydrocortisone treatment"/>
 <result pre="and hypoglycemia [65]. Severe pneumonia or any features of acute" exact="adrenal insufficiency" post="would warrant IV or IM hydrocortisone treatment with 100"/>
 <result pre="divided doses, accompanied with appropriate fluid resuscitation [66]. Patients with" exact="primary" post="adrenal insufficiency would not require additional fludrocortisone in this"/>
 <result pre="doses, accompanied with appropriate fluid resuscitation [66]. Patients with primary" exact="adrenal insufficiency" post="would not require additional fludrocortisone in this setting as"/>
 <result pre="COVID-19 patients [67, 68]. However, steroids in physiological doses for" exact="adrenal insufficiency" post="would be beneficial and improve the outcomes in these"/>
 <result pre="(see the following section). B. COVID-19 and Critical Illness-Related Corticosteroid" exact="Insufficiency" post="Usually, any stressful condition including infections results in activation"/>
 <result pre="and Critical Illness-Related Corticosteroid Insufficiency Usually, any stressful condition including" exact="infections" post="results in activation of the HPA axis with increased"/>
 <result pre="corticosteroid insufficiency (CIRCI) [69]. The occurrence of CIRCI during an" exact="infection" post="is associated with increased inflammatory markers, abnormalities in indicators"/>
 <result pre="Although uncommon, these patients may also demonstrate hyperkalemia, hyponatremia, and" exact="hypoglycemia" post="[69, 70]. Based on the available evidence, a random"/>
 <result pre="with slow tapering of doses once the patientâ€™s condition is" exact="stable" post="[70]. The decision regarding hydrocortisone treatment should be made"/>
 <result pre="and corticosteroids may be harmful [35]. C. COVID-19 and Cushingâ€™s" exact="Syndrome" post="Patients with Cushingâ€™s syndrome (CS) may experience delays in"/>
 <result pre="harmful [35]. C. COVID-19 and Cushingâ€™s Syndrome Patients with Cushingâ€™s" exact="syndrome" post="(CS) may experience delays in diagnostic evaluation and surgical"/>
 <result pre="with CS are likely to result in a poor prognosis." exact="Diabetes" post="and hypertension characteristically seen in CS have been identified"/>
 <result pre="are likely to result in a poor prognosis. Diabetes and" exact="hypertension" post="characteristically seen in CS have been identified as well-known"/>
 <result pre="CS patients [74]. These patients may be susceptible to severe" exact="pneumonia" post="with secondary bacterial infections from changes in white blood"/>
 <result pre="[74]. These patients may be susceptible to severe pneumonia with" exact="secondary" post="bacterial infections from changes in white blood cell count"/>
 <result pre="These patients may be susceptible to severe pneumonia with secondary" exact="bacterial infections" post="from changes in white blood cell count and function,"/>
 <result pre="patients may be susceptible to severe pneumonia with secondary bacterial" exact="infections" post="from changes in white blood cell count and function,"/>
 <result pre="to CD8 ratio, and reduced action of natural killer cells" exact="secondary" post="to glucocorticoid excess [75]. Coagulopathy associated with elevated D-dimer"/>
 <result pre="degradation of ACE2, thereby up regulating the RAAS, resulting in" exact="hypokalemia" post="[54]. Hypokalemia can be more severe in patients with"/>
 <result pre="with COVID-19. Therefore, it is crucial to adhere to standard" exact="infection" post="prevention measures. During an infection, blood pressure and blood"/>
 <result pre="should be considered for patients with active CS until the" exact="infection" post="settles and they are stable to undergo definitive therapy."/>
 <result pre="with active CS until the infection settles and they are" exact="stable" post="to undergo definitive therapy. Intravenous etomidate can be considered"/>
 <result pre="achieve a target cortisol level. If the patient has coexisting" exact="acute" post="kidney injury, further stringent dose titration is warranted. It"/>
 <result pre="a target cortisol level. If the patient has coexisting acute" exact="kidney injury," post="further stringent dose titration is warranted. It is crucial"/>
 <result pre="may crossreact in many assays [79, 80]. D. COVID-19 and" exact="Pheochromocytoma" post="and Paraganglioma Because of the current COVID-19 pandemic, regular"/>
 <result pre="in many assays [79, 80]. D. COVID-19 and Pheochromocytoma and" exact="Paraganglioma" post="Because of the current COVID-19 pandemic, regular follow-up of"/>
 <result pre="patients are not at an increased risk of contracting the" exact="infection" post="and general disease prevention measures can be followed. If"/>
 <result pre="at an increased risk of contracting the infection and general" exact="disease" post="prevention measures can be followed. If infected with SARS-CoV-2,"/>
 <result pre="adequate Î± -adrenoreceptor blockade, can be considered to prevent possible" exact="cardiovascular" post="complications [82]. 5. Thyroid A report on thyroid function"/>
 <result pre="can be considered to prevent possible cardiovascular complications [82]. 5." exact="Thyroid" post="A report on thyroid function tests in 48 patients"/>
 <result pre="reduced in these patients, raising the possibility of either central" exact="hypothyroidism" post="or the â€œsick euthyroidâ€� syndrome [83]. In another follow-up"/>
 <result pre="the possibility of either central hypothyroidism or the â€œsick euthyroidâ€�" exact="syndrome" post="[83]. In another follow-up study that looked at endocrine"/>
 <result pre="having subclinical thyrotoxicosis, 3 had central hypothyroidism, and 1 had" exact="primary" post="hypothyroidism with positive thyroid autoantibodies [41]. The degree of"/>
 <result pre="subclinical thyrotoxicosis, 3 had central hypothyroidism, and 1 had primary" exact="hypothyroidism" post="with positive thyroid autoantibodies [41]. The degree of hormonal"/>
 <result pre="derangement and clinical features were not described. Therefore, previously undiagnosed" exact="primary" post="hypothyroidism and recovering central hypothyroidism or sick euthyroidism are"/>
 <result pre="and clinical features were not described. Therefore, previously undiagnosed primary" exact="hypothyroidism" post="and recovering central hypothyroidism or sick euthyroidism are possibilities"/>
 <result pre="not described. Therefore, previously undiagnosed primary hypothyroidism and recovering central" exact="hypothyroidism" post="or sick euthyroidism are possibilities that should be considered."/>
 <result pre="hypothyroidism or sick euthyroidism are possibilities that should be considered." exact="Acute" post="and chronic phases of critical illness have different effects"/>
 <result pre="sick euthyroidism are possibilities that should be considered. Acute and" exact="chronic" post="phases of critical illness have different effects on the"/>
 <result pre="have different effects on the thyroid axis [84]. Sick euthyroid" exact="syndrome" post="or â€œnonthyroidal illness syndromeâ€� can manifest in patients with"/>
 <result pre="syndromeâ€� can manifest in patients with COVID-19, especially during the" exact="acute" post="and recovery phase of the illness, which will further"/>
 <result pre="further complicate their management. This mechanism is complex. During an" exact="acute" post="illness, changes in thyroid hormone binding, cellular uptake, and"/>
 <result pre="in thyroid hormone binding, cellular uptake, and decreased activity of" exact="type I" post="deiodinase enzyme leading to decreased T4 to T3 conversion,"/>
 <result pre="leading to decreased T4 to T3 conversion, can occur [84]." exact="Type I" post="deiodinase enzyme activity is reduced as it is influenced"/>
 <result pre="free fatty acids, and various drugs used in management [84]." exact="Increased" post="T3 catabolism in peripheral tissues can occur because of"/>
 <result pre="various drugs used in management [84]. Increased T3 catabolism in" exact="peripheral" post="tissues can occur because of increased activity of type"/>
 <result pre="in peripheral tissues can occur because of increased activity of" exact="type 3" post="deiodinase [84]. The cumulative effect is low circulating T3"/>
 <result pre="during the course of illness [84]. Differentiating this from central" exact="hypothyroidism" post="might be difficult in the acute stage and may"/>
 <result pre="Differentiating this from central hypothyroidism might be difficult in the" exact="acute" post="stage and may require reevaluation later. If nonthyroidal illness"/>
 <result pre="acute stage and may require reevaluation later. If nonthyroidal illness" exact="syndrome" post="is suspected, therapy with thyroxine or liothyronine is not"/>
 <result pre="5 patients showed destruction of follicular epithelia and exfoliation of" exact="epithelial" post="cells into the follicles. There was also evidence of"/>
 <result pre="as well as a reduced amount of thyroglobulin in follicular" exact="epithelial" post="cells in all 4 patients who died of SARS"/>
 <result pre="autopsy study involving 4 patients who died of SARS-CoV-1, neither" exact="viral" post="RNA material nor antigens were seen in the thyroid"/>
 <result pre="thyroid [87]. A recent report from Italy on a young" exact="female" post="who recovered from SARS-CoV-2 describes the first reported case"/>
 <result pre="who recovered from SARS-CoV-2 describes the first reported case of" exact="subacute thyroiditis" post="chronologically related to this viral infection [88]. With the"/>
 <result pre="recovered from SARS-CoV-2 describes the first reported case of subacute" exact="thyroiditis" post="chronologically related to this viral infection [88]. With the"/>
 <result pre="first reported case of subacute thyroiditis chronologically related to this" exact="viral infection" post="[88]. With the known association of subacute thyroiditis with"/>
 <result pre="reported case of subacute thyroiditis chronologically related to this viral" exact="infection" post="[88]. With the known association of subacute thyroiditis with"/>
 <result pre="to this viral infection [88]. With the known association of" exact="subacute thyroiditis" post="with preceding viral infections, it is possible that the"/>
 <result pre="this viral infection [88]. With the known association of subacute" exact="thyroiditis" post="with preceding viral infections, it is possible that the"/>
 <result pre="[88]. With the known association of subacute thyroiditis with preceding" exact="viral" post="infections, it is possible that the thyroiditis is etiologically"/>
 <result pre="thyroiditis with preceding viral infections, it is possible that the" exact="thyroiditis" post="is etiologically related to SARS-CoV-2 infection. A. Management Considerations"/>
 <result pre="etiologically related to SARS-CoV-2 infection. A. Management Considerations of Preexisting" exact="Thyroid" post="Conditions If infected with COVID-19, patients with central hypothyroidism"/>
 <result pre="Preexisting Thyroid Conditions If infected with COVID-19, patients with central" exact="hypothyroidism" post="and primary hypothyroidism should be advised to continue the"/>
 <result pre="Conditions If infected with COVID-19, patients with central hypothyroidism and" exact="primary" post="hypothyroidism should be advised to continue the same dose"/>
 <result pre="If infected with COVID-19, patients with central hypothyroidism and primary" exact="hypothyroidism" post="should be advised to continue the same dose or"/>
 <result pre="drugs would need to exercise extra caution because signs of" exact="neutropenia" post="and COVID-19 could mimic each other. Urgent medical care"/>
 <result pre="recommended. Consultation is advisable in situations such as pregnancy, poor" exact="disease" post="control, and patients with adverse effects to medications. Definitive"/>
 <result pre="feasible for a considerable period [89]. In patients with underlying" exact="thyroid disease" post="during an acute illness, thyroid function may not depict"/>
 <result pre="for a considerable period [89]. In patients with underlying thyroid" exact="disease" post="during an acute illness, thyroid function may not depict"/>
 <result pre="period [89]. In patients with underlying thyroid disease during an" exact="acute" post="illness, thyroid function may not depict the actual thyroid"/>
 <result pre="patients who are on glucocorticoids and mycophenolate mofetil for thyroid" exact="eye disease" post="should especially adhere to social distancing and infection control"/>
 <result pre="who are on glucocorticoids and mycophenolate mofetil for thyroid eye" exact="disease" post="should especially adhere to social distancing and infection control"/>
 <result pre="thyroid eye disease should especially adhere to social distancing and" exact="infection" post="control measures because of the potential risk of complications."/>
 <result pre="islet cells [93]. It is not known whether the SARS-CoV" exact="infection" post="alters the patterns of pancreatic cell ACE2 expression, dependent"/>
 <result pre="ethnic or other variations. In fact, animal studies have shown" exact="diabetes" post="to increase ACE2 expression in pancreatic as well as"/>
 <result pre="ACE2 expression in islet cells and a high incidence of" exact="hyperglycemia" post="among SARS patients. The authors speculated that SARS-CoV-1 may"/>
 <result pre="may directly infect islet cells causing their dysfunction, resulting in" exact="hyperglycemia" post="or new-onset diabetes [92]. Pancreatic injury (hydropic degeneration, fatty"/>
 <result pre="islet cells causing their dysfunction, resulting in hyperglycemia or new-onset" exact="diabetes" post="[92]. Pancreatic injury (hydropic degeneration, fatty degeneration, and interstitial"/>
 <result pre="postmortem studies [95] but not in others [96]. Similarly, SARS-CoV-1" exact="viral" post="material was found within pancreatic cells in some [87],"/>
 <result pre="insulin resistance to establish a direct link between the coronavirus" exact="infection" post="and hyperglycemia. Viral infections are known to cause type"/>
 <result pre="establish a direct link between the coronavirus infection and hyperglycemia." exact="Viral" post="infections are known to cause type 1 diabetes by"/>
 <result pre="a direct link between the coronavirus infection and hyperglycemia. Viral" exact="infections" post="are known to cause type 1 diabetes by triggering"/>
 <result pre="coronavirus infection and hyperglycemia. Viral infections are known to cause" exact="type 1" post="diabetes by triggering the production of cross-reactive antibodies as"/>
 <result pre="and hyperglycemia. Viral infections are known to cause type 1" exact="diabetes" post="by triggering the production of cross-reactive antibodies as a"/>
 <result pre="cohort of 39 nondiabetic nonglucocorticoid-treated patients, 20 developed new-onset fasting" exact="hyperglycemia" post="(&amp;gt;7 mmol/L), starting from the third day in the"/>
 <result pre="weeks in the majority, whereas 2 patients continued to have" exact="diabetes" post="3 years later [92]. This was not observed in"/>
 <result pre="current COVID-19 pandemic are limited. One study among patients with" exact="diabetes" post="and COVID-19 reported that preprandial and postprandial glucose levels"/>
 <result pre="COVID-19 patients note a higher incidence of hyperglycemia, new-onset diabetes," exact="diabetic ketoacidosis," post="and euglycemic ketoacidosis [100]. Any infection or acute illness"/>
 <result pre="hyperglycemia, new-onset diabetes, diabetic ketoacidosis, and euglycemic ketoacidosis [100]. Any" exact="infection" post="or acute illness would trigger inflammatory and stress responses"/>
 <result pre="diabetes, diabetic ketoacidosis, and euglycemic ketoacidosis [100]. Any infection or" exact="acute" post="illness would trigger inflammatory and stress responses with increase"/>
 <result pre="data remain too scarce to confirm that coronavirus-infected patients develop" exact="hyperglycemia" post="at a greater severity or frequency, beyond what is"/>
 <result pre="greater severity or frequency, beyond what is expected in any" exact="acute" post="severe illness. Irrespective of the cause, hyperglycemia predicts a"/>
 <result pre="expected in any acute severe illness. Irrespective of the cause," exact="hyperglycemia" post="predicts a poor prognosis and warrants prompt recognition and"/>
 <result pre="risk. SARS-CoV infects alveolar cells and pancreatic islet cells, causes" exact="hyperglycemia" post="resulting from islet cell dysfunction, and this increases glycosylation"/>
 <result pre="islet cell dysfunction, and this increases glycosylation of ACE2 and" exact="viral" post="spike proteins facilitating viral entry in to host cells"/>
 <result pre="this increases glycosylation of ACE2 and viral spike proteins facilitating" exact="viral" post="entry in to host cells and thus setting up"/>
 <result pre="injury may predispose to hypoglycemia. However, an excess risk of" exact="hypoglycemia" post="was not described during the SARS epidemic. One reported"/>
 <result pre="described during the SARS epidemic. One reported event of fatal" exact="hypoglycemic coma" post="affected a patient with diabetes; however, the antidiabetic therapies"/>
 <result pre="not described [102]. The same author noted an increased incidence" exact="of liver" post="injury among patients with diabetes and SARS, which may"/>
 <result pre="noted an increased incidence of liver injury among patients with" exact="diabetes" post="and SARS, which may also contribute to hypoglycemia [102]."/>
 <result pre="patients with diabetes and SARS, which may also contribute to" exact="hypoglycemia" post="[102]. To date, no link between alpha-cell function or"/>
 <result pre="no link between alpha-cell function or glucagon levels and coronavirus" exact="infections" post="have been described. B. Pancreatitis Despite widespread expression of"/>
 <result pre="B. Pancreatitis Despite widespread expression of ACE2 in pancreatic tissues," exact="pancreatitis" post="has been uncommon with coronavirus infections. No events of"/>
 <result pre="pancreatitis has been uncommon with coronavirus infections. No events of" exact="pancreatitis" post="have been described during the SARS-CoV-1 or MERS-CoV epidemics"/>
 <result pre="described during the SARS-CoV-1 or MERS-CoV epidemics attributable to the" exact="viral infection." post="During the current COVID-19 pandemic, mild pancreatitis (diagnosed on"/>
 <result pre="to the viral infection. During the current COVID-19 pandemic, mild" exact="pancreatitis" post="(diagnosed on the basis of elevated serum amylase and/or"/>
 <result pre="current COVID-19 pandemic, mild pancreatitis (diagnosed on the basis of" exact="elevated serum" post="amylase and/or lipase) has been described in patients with"/>
 <result pre="whether the mild pancreatic injury was a result of direct" exact="viral" post="invasion or the systemic inflammatory response. Nevertheless, it is"/>
 <result pre="injury was a result of direct viral invasion or the" exact="systemic" post="inflammatory response. Nevertheless, it is important to recognize this"/>
 <result pre="inflammatory response. Nevertheless, it is important to recognize this because" exact="pancreatitis" post="itself could worsen ARDS, the major life-threatening sequelae of"/>
 <result pre="major life-threatening sequelae of COVID-19. C. COVID-19 in People with" exact="Diabetes" post="Prognostic and management implications of possible pancreatic injury on"/>
 <result pre="injury on patients with COVID-19 and on people with preexisting" exact="diabetes" post="are reviewed in detail elsewhere [103â€&quot;105]. In brief, people"/>
 <result pre="are reviewed in detail elsewhere [103â€&quot;105]. In brief, people with" exact="diabetes" post="should ensure a healthy lifestyle, regular glucose monitoring, and"/>
 <result pre="glucose monitoring, and adherence to pharmacotherapy during this pandemic. Although" exact="diabetes" post="does not increase the risk of infection, it increases"/>
 <result pre="risk for complications and death [74, 106]. Obesity, hypertension, and" exact="cardiovascular" post="diseases are common comorbidities of diabetes and are all"/>
 <result pre="106]. Obesity, hypertension, and cardiovascular diseases are common comorbidities of" exact="diabetes" post="and are all linked with adverse outcomes with COVID-19"/>
 <result pre="cautious use [103]. D. COVID-19 in Patients with Pancreatic Neuroendocrine" exact="Tumors" post="Whether patients with these rare disorders are more susceptible"/>
 <result pre="(infarct or necrosis) in these patients is unknown. Patients with" exact="glucagonoma" post="may be at increased risk of severe COVID-19 because"/>
 <result pre="may be at increased risk of severe COVID-19 because of" exact="hyperglycemia" post="and a thrombophilic state [110]. Patients on immunosuppressive therapies"/>
 <result pre="patients during the COVID-19 pandemic are reviewed elsewhere [111]. 7." exact="Parathyroid" post="Although there is no evidence that primary hyper- or"/>
 <result pre="elsewhere [111]. 7. Parathyroid Although there is no evidence that" exact="primary" post="hyper- or hypoparathyroidism are risk factors for COVID-19, any"/>
 <result pre="Parathyroid Although there is no evidence that primary hyper- or" exact="hypoparathyroidism" post="are risk factors for COVID-19, any infection may impose"/>
 <result pre="primary hyper- or hypoparathyroidism are risk factors for COVID-19, any" exact="infection" post="may impose challenges in the management of these diseases."/>
 <result pre="impose challenges in the management of these diseases. Patients with" exact="chronic" post="renal impairment and parathyroid dysfunction may be at risk"/>
 <result pre="may be at risk for COVID-19 because of the underlying" exact="renal disease." post="Intracellular calcium signaling is essential for the replication of"/>
 <result pre="and needs further research. No data exist on ACE2 expression," exact="viral" post="invasion or inflammation of the parathyroid glands, or alterations"/>
 <result pre="in parathyroid hormone or calcium homeostasis during coronavirus infections. Although" exact="hypocalcemia" post="has been reported in patients with severe illnesses in"/>
 <result pre="in the past, no published data are available regarding COVID-19" exact="disease" post="severity and serum calcium levels. Unpublished data suggest a"/>
 <result pre="serum calcium levels. Unpublished data suggest a possible association between" exact="hypocalcemia" post="and COVID-19 disease severity and prognosis. A. Management Considerations"/>
 <result pre="Unpublished data suggest a possible association between hypocalcemia and COVID-19" exact="disease" post="severity and prognosis. A. Management Considerations of Preexisting Hypoparathyroidism"/>
 <result pre="COVID-19 disease severity and prognosis. A. Management Considerations of Preexisting" exact="Hypoparathyroidism" post="The availability of calcium supplements must be ensured for"/>
 <result pre="availability of calcium supplements must be ensured for patients with" exact="hypoparathyroidism" post="to prevent life-threatening complications of hypocalcemia. Patients with hypoparathyroidism"/>
 <result pre="with hypoparathyroidism to prevent life-threatening complications of hypocalcemia. Patients with" exact="hypoparathyroidism" post="should have access to their endocrine service provider if"/>
 <result pre="and signs, pending laboratory confirmation of hypocalcemia. For patients with" exact="hyperparathyroidism" post="awaiting surgery, timing of parathyroid surgery must be considered"/>
 <result pre="role in the immune system and reduces the risk of" exact="viral" post="infections in many ways. The beneficial role of vitamin"/>
 <result pre="in the immune system and reduces the risk of viral" exact="infections" post="in many ways. The beneficial role of vitamin D"/>
 <result pre="adaptive immunity [116]. Dancer et al. showed that vitamin D" exact="deficiency" post="is a common problem in patients with ARDS and"/>
 <result pre="in patients with ARDS and leads to inflammation in alveolar" exact="epithelial" post="cells. They also showed that repletion of vitamin D"/>
 <result pre="D-binding protein relating to differences in the inflammatory profile and" exact="disease" post="severity has been demonstrated in tuberculosis patients [118]. Increased"/>
 <result pre="the inflammatory profile and disease severity has been demonstrated in" exact="tuberculosis" post="patients [118]. Increased serum levels of pro-inflammatory cytokines associated"/>
 <result pre="and disease severity has been demonstrated in tuberculosis patients [118]." exact="Increased" post="serum levels of pro-inflammatory cytokines associated with pulmonary inflammation"/>
 <result pre="patients [118]. Increased serum levels of pro-inflammatory cytokines associated with" exact="pulmonary" post="inflammation and lung injury have been reported in studies"/>
 <result pre="MCP1, MIP1A, and TNF-Î±) were found to be associated with" exact="disease" post="severity [36]. Vitamin D treatment seems to inhibit the"/>
 <result pre="serum levels of pro-inflammatory cytokines TNF-Î± and IFN-Î³ [121]. SARS-CoV-2" exact="infection" post="also results in an increase in the levels of"/>
 <result pre="as it has been demonstrated that treatment of vitamin D" exact="deficiency" post="leads to reduced expression of DPP4/CD26 [123, 124]. The"/>
 <result pre="mechanisms (Fig. 2) thus suggest that treatment of vitamin D" exact="deficiency" post="may be of benefit in the prevention and treatment"/>
 <result pre="entry. However, upregulation of ACE 2, protects against lipopolysaccharide induced" exact="acute" post="lung injury. Vitamin D is found to be a"/>
 <result pre="action. ACE1, angiotensin-converting enzyme 1; ACE2, angiotensin-converting enzyme 2; AT1R," exact="type 1" post="angiotensin 2 receptor; AT1-7, heptapeptide angiotensin (1-7); DPP4/CD26, dipeptidyl"/>
 <result pre="assumptions can be made regarding the role of vitamin D" exact="deficiency" post="in COVID-19 and disease severity based on the epidemiological"/>
 <result pre="regarding the role of vitamin D deficiency in COVID-19 and" exact="disease" post="severity based on the epidemiological and clinical data. Conditions"/>
 <result pre="based on the epidemiological and clinical data. Conditions associated with" exact="lower" post="vitamin D levels such as chronic illnesses, smoking, and"/>
 <result pre="data. Conditions associated with lower vitamin D levels such as" exact="chronic" post="illnesses, smoking, and increased age and dark-skinned ethnicities have"/>
 <result pre="activities and socioeconomic status. A. Vitamin D Replacement Although increased" exact="susceptibility to" post="infections has been found with vitamin D deficiency, evidence"/>
 <result pre="socioeconomic status. A. Vitamin D Replacement Although increased susceptibility to" exact="infections" post="has been found with vitamin D deficiency, evidence regarding"/>
 <result pre="evidence regarding the benefits of vitamin D supplementation in preventing" exact="infections" post="or disease mortality has been inconsistent [130]. A meta-analysis"/>
 <result pre="the benefits of vitamin D supplementation in preventing infections or" exact="disease" post="mortality has been inconsistent [130]. A meta-analysis that showed"/>
 <result pre="meta-analysis that showed vitamin D supplementation reduced the risk of" exact="acute" post="respiratory tract infections demonstrated benefits with daily or weekly"/>
 <result pre="that showed vitamin D supplementation reduced the risk of acute" exact="respiratory" post="tract infections demonstrated benefits with daily or weekly vitamin"/>
 <result pre="vitamin D supplementation reduced the risk of acute respiratory tract" exact="infections" post="demonstrated benefits with daily or weekly vitamin D supplementation,"/>
 <result pre="Protective effects were strongest in those with profound vitamin D" exact="deficiency" post="at baseline [131]. Different thresholds of vitamin D levels"/>
 <result pre="levels have been recommended in studies for the protection of" exact="respiratory" post="tract infections. A vitamin D threshold ofâ€…&amp;gt;â€…50nmol/L (20 ng/mL)"/>
 <result pre="ng/mL) is thought to be adequate for the prevention of" exact="acute" post="respiratory tract infections [132]. The degree of protection appears"/>
 <result pre="is thought to be adequate for the prevention of acute" exact="respiratory" post="tract infections [132]. The degree of protection appears to"/>
 <result pre="to be adequate for the prevention of acute respiratory tract" exact="infections" post="[132]. The degree of protection appears to be optimal"/>
 <result pre="was required to achieve this level during winter months because" exact="cutaneous" post="vitamin D synthesis is minimal during this period [133]."/>
 <result pre="of the inflammatory response, epidemiological data on protection from severe" exact="infection" post="and established safety, it is reasonable to consider vitamin"/>
 <result pre="to consider vitamin D replacement in patients with demonstrable deficiency." exact="Limited" post="exposure to sunlight, and poor dietary conditions as a"/>
 <result pre="spermatogonia and spermatids. This is shown to be used for" exact="viral" post="S protein priming [138]. This suggests that the testis"/>
 <result pre="in ovaries. To date, there are no reports on the" exact="viral" post="distribution or pathological effects of virus on human gonads"/>
 <result pre="in 2003 using autopsy samples of 2 male and 2" exact="female" post="patients who died of SARS in China revealed that"/>
 <result pre="autopsy-based study on 6 males who died of SARS-CoV-1 showed" exact="orchitis" post="in all. There was marked germ cell destruction, reduced"/>
 <result pre="basement membrane, and leukocyte infiltration. In situ hybridization for SARS" exact="viral" post="genomic material was negative in the samples. Therefore, the"/>
 <result pre="immune-mediated damage as the cause of destruction rather than direct" exact="viral" post="entry and damage [139]. There is no literature on"/>
 <result pre="human ovaries. The available evidence suggests the vulnerability of the" exact="testes" post="to viral entry because the abundance of ACE2 has"/>
 <result pre="The available evidence suggests the vulnerability of the testes to" exact="viral" post="entry because the abundance of ACE2 has not been"/>
 <result pre="has not been demonstrated during SARS-CoV-1 epidemic. Even in the" exact="absence of" post="viral material, immune-mediated orchitis was shown during the previous"/>
 <result pre="been demonstrated during SARS-CoV-1 epidemic. Even in the absence of" exact="viral" post="material, immune-mediated orchitis was shown during the previous epidemic,"/>
 <result pre="SARS-CoV-1 epidemic. Even in the absence of viral material, immune-mediated" exact="orchitis" post="was shown during the previous epidemic, the same consequence"/>
 <result pre="survivors of the current pandemic. Therefore, further studies to assess" exact="hypogonadism" post="and spermatogenesis following recovery from acute illness are warranted."/>
 <result pre="further studies to assess hypogonadism and spermatogenesis following recovery from" exact="acute" post="illness are warranted. A. Management Considerations of Preexistent Hypogonadism"/>
 <result pre="from acute illness are warranted. A. Management Considerations of Preexistent" exact="Hypogonadism" post="For people with hypogonadism, continuing the same regimen of"/>
 <result pre="of the next testosterone injection [58]. In the case of" exact="female" post="hormone replacement, it may be preferable to use transdermal"/>
 <result pre="to lead to a hypercoagulable state. 10. Conclusions In the" exact="absence of" post="literature relating to the effects of SARS-CoV-2 on endocrine"/>
 <result pre="we have made speculations based on the evidence from SARS-CoV-1" exact="infection" post="during the years 2002 through 2003. Research on clinical"/>
 <result pre="effect of SARS-Cov-2 on the endocrine system. Furthermore, studies on" exact="viral" post="genomics to fill the gaps in the knowledge on"/>
 <result pre="fill the gaps in the knowledge on effects of direct" exact="viral" post="invasion and immune-mediated injury are needed. Clinicians should be"/>
 <result pre="which are mostly empirical. Abbreviations ACE2 angiotensin-converting enzyme 2 ARDS" exact="acute" post="respiratory distress syndrome CIRCI critical illness-related corticosteroid insufficiency COVID-19"/>
 <result pre="are mostly empirical. Abbreviations ACE2 angiotensin-converting enzyme 2 ARDS acute" exact="respiratory" post="distress syndrome CIRCI critical illness-related corticosteroid insufficiency COVID-19 coronavirus-19"/>
 <result pre="empirical. Abbreviations ACE2 angiotensin-converting enzyme 2 ARDS acute respiratory distress" exact="syndrome" post="CIRCI critical illness-related corticosteroid insufficiency COVID-19 coronavirus-19 CS Cushing"/>
 <result pre="distress syndrome CIRCI critical illness-related corticosteroid insufficiency COVID-19 coronavirus-19 CS" exact="Cushing" post="syndrome DRA dopamine receptor agonist FGF2 fibroblast growth factor"/>
 <result pre="syndrome CIRCI critical illness-related corticosteroid insufficiency COVID-19 coronavirus-19 CS Cushing" exact="syndrome" post="DRA dopamine receptor agonist FGF2 fibroblast growth factor 2"/>
 <result pre="growth factor 2 HPA hypothalamo-pituitary-adrenal axis IFN-Î³ interferon Î³ MCP1" exact="monocyte" post="chemoattractant protein 1 MERS-CoV Middle East respiratory syndrome-coronavirus RAAS"/>
 <result pre="interferon Î³ MCP1 monocyte chemoattractant protein 1 MERS-CoV Middle East" exact="respiratory" post="syndrome-coronavirus RAAS renin-angiotensin-aldosterone system S protein Spike protein SARS-CoV-1"/>
 <result pre="syndrome-coronavirus RAAS renin-angiotensin-aldosterone system S protein Spike protein SARS-CoV-1 severe" exact="acute" post="respiratory syndrome-coronavirus-1 SARS-CoV-2 severe acute respiratory syndrome-coronavirus-2 TMPRSS2 transmembrane"/>
 <result pre="RAAS renin-angiotensin-aldosterone system S protein Spike protein SARS-CoV-1 severe acute" exact="respiratory" post="syndrome-coronavirus-1 SARS-CoV-2 severe acute respiratory syndrome-coronavirus-2 TMPRSS2 transmembrane protease"/>
 <result pre="protein Spike protein SARS-CoV-1 severe acute respiratory syndrome-coronavirus-1 SARS-CoV-2 severe" exact="acute" post="respiratory syndrome-coronavirus-2 TMPRSS2 transmembrane protease serine 2 Additional Information"/>
 <result pre="Spike protein SARS-CoV-1 severe acute respiratory syndrome-coronavirus-1 SARS-CoV-2 severe acute" exact="respiratory" post="syndrome-coronavirus-2 TMPRSS2 transmembrane protease serine 2 Additional Information Disclosure"/>
 <result pre="study. References References 1.MulateroP, StowasserM, LohKC, et al.Increased diagnosis of" exact="primary" post="aldosteronism, including surgically correctable forms, in centers from five"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-732007143"/>
 <result pre="coronavirus-induced lung injury. Nat Med.2005;11(8):875-879.16007097 9.ZhouP, YangX-L, WangX-G, et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="blocker. Am J Hypertens.2015;28(1):15-21.24842388 16.KubaK, ImaiY, PenningerJMAngiotensin-converting enzyme 2 in" exact="lung diseases." post="Curr Opin Pharmacol.2006;6(3):271-276.16581295 17.IwaiM, HoriuchiMDevil and angel in the"/>
 <result pre="of the reninâ€&quot;angiotensin system be withdrawn in patients with COVID-19?Eur" exact="Heart" post="J. March 2020. doi:10.1093/eurheartj/ehaa235 19.de WildeAH, SnijderEJ, KikkertM, van"/>
 <result pre="HongZS, et al.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak - an update on the status."/>
 <result pre="Science (80-). 2020. doi:10.1126/science.aax0902 29.GuJ, KortewegCPathology and pathogenesis of severe" exact="acute" post="respiratory syndrome. Am J Pathol.2007;170(4):1136-1147.17392154 30.KeichoN, ItoyamaS, KashiwaseK, et"/>
 <result pre="(80-). 2020. doi:10.1126/science.aax0902 29.GuJ, KortewegCPathology and pathogenesis of severe acute" exact="respiratory" post="syndrome. Am J Pathol.2007;170(4):1136-1147.17392154 30.KeichoN, ItoyamaS, KashiwaseK, et al.Association"/>
 <result pre="al.Association of human leukocyte antigen class II alleles with severe" exact="acute" post="respiratory syndrome in the Vietnamese population. Hum Immunol.2009;70(7):527-531.19445991 31.ChenYM,"/>
 <result pre="of human leukocyte antigen class II alleles with severe acute" exact="respiratory" post="syndrome in the Vietnamese population. Hum Immunol.2009;70(7):527-531.19445991 31.ChenYM, LiangSY,"/>
 <result pre="human leukocyte antigen class II alleles with severe acute respiratory" exact="syndrome" post="in the Vietnamese population. Hum Immunol.2009;70(7):527-531.19445991 31.ChenYM, LiangSY, ShihYP,"/>
 <result pre="31.ChenYM, LiangSY, ShihYP, et al.Epidemiological and genetic correlates of severe" exact="acute" post="respiratory syndrome coronavirus infection in the hospital with the"/>
 <result pre="LiangSY, ShihYP, et al.Epidemiological and genetic correlates of severe acute" exact="respiratory" post="syndrome coronavirus infection in the hospital with the highest"/>
 <result pre="ShihYP, et al.Epidemiological and genetic correlates of severe acute respiratory" exact="syndrome" post="coronavirus infection in the hospital with the highest nosocomial"/>
 <result pre="al.Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus" exact="infection" post="in the hospital with the highest nosocomial infection rate"/>
 <result pre="respiratory syndrome coronavirus infection in the hospital with the highest" exact="nosocomial infection" post="rate in Taiwan in 2003. J Clin Microbiol2006;44(2):359-365.16455884 32.WangSF,"/>
 <result pre="syndrome coronavirus infection in the hospital with the highest nosocomial" exact="infection" post="rate in Taiwan in 2003. J Clin Microbiol2006;44(2):359-365.16455884 32.WangSF,"/>
 <result pre="II DR 0301 genotypes are associated with resistance to severe" exact="acute" post="respiratory syndrome (SARS) infection. Viral Immunol.2011;24(5):421-426.21958371 33.XuZ, ShiL, WangY,"/>
 <result pre="DR 0301 genotypes are associated with resistance to severe acute" exact="respiratory" post="syndrome (SARS) infection. Viral Immunol.2011;24(5):421-426.21958371 33.XuZ, ShiL, WangY, et"/>
 <result pre="0301 genotypes are associated with resistance to severe acute respiratory" exact="syndrome" post="(SARS) infection. Viral Immunol.2011;24(5):421-426.21958371 33.XuZ, ShiL, WangY, et al.Pathological"/>
 <result pre="associated with resistance to severe acute respiratory syndrome (SARS) infection." exact="Viral" post="Immunol.2011;24(5):421-426.21958371 33.XuZ, ShiL, WangY, et al.Pathological findings of COVID-19"/>
 <result pre="33.XuZ, ShiL, WangY, et al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir Med.2020;8(4):420-422.32085846 34.LinL, LuL, CaoW,"/>
 <result pre="ShiL, WangY, et al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir Med.2020;8(4):420-422.32085846 34.LinL, LuL, CaoW, LiTHypothesis"/>
 <result pre="of SARS-CoV-2 infection-a review of immune changes in patients with" exact="viral pneumonia." post="Emerg Microbes Infect. 2020;9(1):727-732.32196410 35.HiranoT, MurakamiMCOVID-19: a new virus,"/>
 <result pre="2020]. Lancet. 2020;395(10223):497-506.31986264 37.RothanHA, ByrareddySNThe epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreak. J Autoimmun.2020;109:102433.32113704 38.SteardoL, SteardoLJr, ZorecR, VerkhratskyANeuroinfection may"/>
 <result pre="manifestations of COVID-19. Acta Physiol2020;229(3):e13473. 39.NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanSSevere" exact="acute" post="respiratory syndrome coronavirus infection causes neuronal death in the"/>
 <result pre="of COVID-19. Acta Physiol2020;229(3):e13473. 39.NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanSSevere acute" exact="respiratory" post="syndrome coronavirus infection causes neuronal death in the absence"/>
 <result pre="COVID-19. Acta Physiol2020;229(3):e13473. 39.NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanSSevere acute respiratory" exact="syndrome" post="coronavirus infection causes neuronal death in the absence of"/>
 <result pre="Physiol2020;229(3):e13473. 39.NetlandJ, MeyerholzDK, MooreS, CassellM, PerlmanSSevere acute respiratory syndrome coronavirus" exact="infection" post="causes neuronal death in the absence of encephalitis in"/>
 <result pre="MeyerholzDK, MooreS, CassellM, PerlmanSSevere acute respiratory syndrome coronavirus infection causes" exact="neuronal" post="death in the absence of encephalitis in mice transgenic"/>
 <result pre="acute respiratory syndrome coronavirus infection causes neuronal death in the" exact="absence of" post="encephalitis in mice transgenic for human ACE2. J Virol.2008;82(15):7264-7275.18495771"/>
 <result pre="syndrome coronavirus infection causes neuronal death in the absence of" exact="encephalitis" post="in mice transgenic for human ACE2. J Virol.2008;82(15):7264-7275.18495771 40.WuY,"/>
 <result pre="J Virol.2008;82(15):7264-7275.18495771 40.WuY, XuX, ChenZ, et al.Nervous system involvement after" exact="infection" post="with COVID-19 and other coronaviruses. Brain Behav Immun2020;87:18-22.32240762 41.LeowMK,"/>
 <result pre="al.Nervous system involvement after infection with COVID-19 and other coronaviruses." exact="Brain" post="Behav Immun2020;87:18-22.32240762 41.LeowMK, KwekDS, NgAW, OngKC, KawGJ, LeeLSHypocortisolism in"/>
 <result pre="41.LeowMK, KwekDS, NgAW, OngKC, KawGJ, LeeLSHypocortisolism in survivors of severe" exact="acute" post="respiratory syndrome (SARS). Clin Endocrinol (Oxf).2005;63(2):197-202.16060914 42.VladutiuGD, NatelsonBHAssociation of"/>
 <result pre="KwekDS, NgAW, OngKC, KawGJ, LeeLSHypocortisolism in survivors of severe acute" exact="respiratory" post="syndrome (SARS). Clin Endocrinol (Oxf).2005;63(2):197-202.16060914 42.VladutiuGD, NatelsonBHAssociation of medically"/>
 <result pre="NgAW, OngKC, KawGJ, LeeLSHypocortisolism in survivors of severe acute respiratory" exact="syndrome" post="(SARS). Clin Endocrinol (Oxf).2005;63(2):197-202.16060914 42.VladutiuGD, NatelsonBHAssociation of medically unexplained"/>
 <result pre="unexplained fatigue with ACE insertion/deletion polymorphism in Gulf War veterans." exact="Muscle" post="Nerve.2004;30(1):38-43.15221876 43.HoffmannM, Kleine-WeberH, SchroederS, et al.SARS-CoV-2 cell entry depends"/>
 <result pre="44.SriramulaS, XiaH, XuP, LazartiguesEBrain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic" exact="hypertension" post="by inhibiting cyclooxygenase-mediated inflammation. Hypertens (Dallas, Tex 1979). 2015;65(3):577-586."/>
 <result pre="48.VilarL, AbuchamJ, AlbuquerqueJL, et al.Controversial issues in the management of" exact="hyperprolactinemia" post="and prolactinomas - an overview by the Neuroendocrinology Department"/>
 <result pre="prolactinomas - an overview by the Neuroendocrinology Department of the" exact="Brazilian" post="Society of Endocrinology and Metabolism. Arch Endocrinol Metab.2018;62(2):236-263.29768629 49.VardasK,"/>
 <result pre="BloxhamDM, WhiteDK, Ross-RussellRI, Oâ€™DonnellDRThe neuroendocrine stress response and severity of" exact="acute" post="respiratory syncytial virus bronchiolitis in infancy. Intensive Care Med.2004;30(12):2257-2262.15536526"/>
 <result pre="WhiteDK, Ross-RussellRI, Oâ€™DonnellDRThe neuroendocrine stress response and severity of acute" exact="respiratory" post="syncytial virus bronchiolitis in infancy. Intensive Care Med.2004;30(12):2257-2262.15536526 51.Yu-LeeLYProlactin"/>
 <result pre="neuroendocrine stress response and severity of acute respiratory syncytial virus" exact="bronchiolitis" post="in infancy. Intensive Care Med.2004;30(12):2257-2262.15536526 51.Yu-LeeLYProlactin modulation of immune"/>
 <result pre="Clinical CommitteeSociety for Endocrinology Clinical Guidance: inpatient management of cranial" exact="diabetes insipidus." post="Endocr Connect.2018;7(7):G8-G11.29930026 53.FilhoAG, FerreiraAJ, SantosSH, et al.Selective increase of"/>
 <result pre="HuC, SuF, DaiJHypokalemia and clinical implications in patients with coronavirus" exact="disease" post="2019 (COVID-19). medRxiv. January 2020:2020.02.27.20028530. doi:10.1101/2020.02.27.20028530 55.Cycloset, Parlodel (bromocriptine)"/>
 <result pre="HIV. J Int AIDS Soc.2019;22(6):e25322.31183987 57.LinSJ, WuZR, CaoL, et al.Pituitary" exact="tumor" post="suppression by combination of cabergoline and chloroquine. J Clin"/>
 <result pre="2020. 59.DingY, WangH, ShenH, et al.The clinical pathology of severe" exact="acute" post="respiratory syndrome (SARS): a report from China. J Pathol.2003;200(3):282-289.12845623"/>
 <result pre="59.DingY, WangH, ShenH, et al.The clinical pathology of severe acute" exact="respiratory" post="syndrome (SARS): a report from China. J Pathol.2003;200(3):282-289.12845623 60.TresoldiAS,"/>
 <result pre="WangH, ShenH, et al.The clinical pathology of severe acute respiratory" exact="syndrome" post="(SARS): a report from China. J Pathol.2003;200(3):282-289.12845623 60.TresoldiAS, SumiloD,"/>
 <result pre="report from China. J Pathol.2003;200(3):282-289.12845623 60.TresoldiAS, SumiloD, PerrinsM, et al.Increased" exact="infection" post="risk in Addisonâ€™s disease and congenital adrenal hyperplasia. J"/>
 <result pre="Pathol.2003;200(3):282-289.12845623 60.TresoldiAS, SumiloD, PerrinsM, et al.Increased infection risk in Addisonâ€™s" exact="disease" post="and congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2020;105(2):418-429."/>
 <result pre="SumiloD, PerrinsM, et al.Increased infection risk in Addisonâ€™s disease and" exact="congenital adrenal hyperplasia." post="J Clin Endocrinol Metab. 2020;105(2):418-429. doi:10.1210/clinem/dgz006. 61.El-MaoucheD, HargreavesCJ, SinaiiN,"/>
 <result pre="PerrinsM, et al.Increased infection risk in Addisonâ€™s disease and congenital" exact="adrenal hyperplasia." post="J Clin Endocrinol Metab. 2020;105(2):418-429. doi:10.1210/clinem/dgz006. 61.El-MaoucheD, HargreavesCJ, SinaiiN,"/>
 <result pre="of illnesses, stress dosing, and illness sequelae in patients with" exact="congenital adrenal hyperplasia." post="J Clin Endocrinol Metab.2018;103(6):2336-2345.29584889 62.ArltW; collab: Society for Endocrinology"/>
 <result pre="illnesses, stress dosing, and illness sequelae in patients with congenital" exact="adrenal hyperplasia." post="J Clin Endocrinol Metab.2018;103(6):2336-2345.29584889 62.ArltW; collab: Society for Endocrinology"/>
 <result pre="Clinical CommitteeSociety for Endocrinology Endocrine Emergency Guidance: emergency management of" exact="acute" post="adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect.2016;5(5):G1-G3.27935813"/>
 <result pre="CommitteeSociety for Endocrinology Endocrine Emergency Guidance: emergency management of acute" exact="adrenal insufficiency" post="(adrenal crisis) in adult patients. Endocr Connect.2016;5(5):G1-G3.27935813 63.PreteA, TaylorAE,"/>
 <result pre="Guidance: emergency management of acute adrenal insufficiency (adrenal crisis) in" exact="adult" post="patients. Endocr Connect.2016;5(5):G1-G3.27935813 63.PreteA, TaylorAE, BancosI, et al.Prevention of"/>
 <result pre="64.ArltW, BaldewegSE, PearceSHS, SimpsonHL.Clinical management guidance during the COVID-19 pandemic:" exact="adrenal insufficiency." post="Eur J Endocrinol. 2020:1-21. 65.DineenR, ThompsonCJ, SherlockMAdrenal crisis: prevention"/>
 <result pre="Endocrinol. 2020:1-21. 65.DineenR, ThompsonCJ, SherlockMAdrenal crisis: prevention and management in" exact="adult" post="patients. Ther Adv Endocrinol Metab.2019;10:2042018819848218.31223468 66.BornsteinSR, AllolioB, ArltW, et"/>
 <result pre="Endocrinol Metab.2019;10:2042018819848218.31223468 66.BornsteinSR, AllolioB, ArltW, et al.Diagnosis and treatment of" exact="primary" post="adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J"/>
 <result pre="a retrospective cohort study. J Infect.2005;51(2):98-102.16038758 68.Clinical management of severe" exact="acute" post="respiratory infection when COVID-19 is suspectedhttps://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed April 14,"/>
 <result pre="retrospective cohort study. J Infect.2005;51(2):98-102.16038758 68.Clinical management of severe acute" exact="respiratory" post="infection when COVID-19 is suspectedhttps://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed April 14, 2020."/>
 <result pre="cohort study. J Infect.2005;51(2):98-102.16038758 68.Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspectedhttps://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed April 14, 2020. 69.MarikPE,"/>
 <result pre="JonesM, VenkateshBVariability of cortisol assays can confound the diagnosis of" exact="adrenal insufficiency" post="in the critically ill population. Intensive Care Med.2006;32(11):1901-1905.17019540 72.EpperlaN,"/>
 <result pre="in the critically ill population. Intensive Care Med.2006;32(11):1901-1905.17019540 72.EpperlaN, McKiernanFIatrogenic" exact="Cushing" post="syndrome and adrenal insufficiency during concomitant therapy with ritonavir"/>
 <result pre="the critically ill population. Intensive Care Med.2006;32(11):1901-1905.17019540 72.EpperlaN, McKiernanFIatrogenic Cushing" exact="syndrome" post="and adrenal insufficiency during concomitant therapy with ritonavir and"/>
 <result pre="ill population. Intensive Care Med.2006;32(11):1901-1905.17019540 72.EpperlaN, McKiernanFIatrogenic Cushing syndrome and" exact="adrenal insufficiency" post="during concomitant therapy with ritonavir and fluticasone. Springerplus.2015;4:455.26322261 73.PivonelloR,"/>
 <result pre="ritonavir and fluticasone. Springerplus.2015;4:455.26322261 73.PivonelloR, FerrignoR, IsidoriAM, BillerBMK, GrossmanAB, ColaoACovid-19" exact="disease" post="and Cushingâ€™s syndrome: recommendations for a special population with"/>
 <result pre="J. 2020;55(5):2000547.32217650 75.ArandaG, LopezC, Fernandez-RuizR, et al.Circulatory immune cells in" exact="Cushing" post="syndrome: bystanders or active contributors to atherometabolic injury? A"/>
 <result pre="GandoS, et al.ISTH interim guidance on recognition and management of" exact="coagulopathy" post="in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.32338827 77.IsidoriAM, MinnettiM, SbardellaE,"/>
 <result pre="YapYW, NarayananRP, et al.Etomidate in the management of severe Cushingâ€™s" exact="disease" post="and MRSA bacteraemia in a district general hospital in"/>
 <result pre="in a district general hospital in the United Kingdom. Endocrinol" exact="Diabetes" post="Metab Case Rep. 2019;2019. doi:10.1530/EDM-19-0044. 81.YuR, WeiMFalse positive test"/>
 <result pre="Case Rep. 2019;2019. doi:10.1530/EDM-19-0044. 81.YuR, WeiMFalse positive test results for" exact="pheochromocytoma" post="from 2000 to 2008. Exp Clin Endocrinol Diabetes. 2010;118(9):577-585."/>
 <result pre="serum thyroid hormone and parathyroid hormone in patients with severe" exact="acute" post="respiratory syndrome.J Chin Antituberculous Assoc.2003;25:232-234. 84.JonklaasJ, BiancoAC, BauerAJ, et"/>
 <result pre="thyroid hormone and parathyroid hormone in patients with severe acute" exact="respiratory" post="syndrome.J Chin Antituberculous Assoc.2003;25:232-234. 84.JonklaasJ, BiancoAC, BauerAJ, et al.;"/>
 <result pre="syndrome.J Chin Antituberculous Assoc.2003;25:232-234. 84.JonklaasJ, BiancoAC, BauerAJ, et al.; collab:" exact="American" post="Thyroid Association Task Force on Thyroid Hormone ReplacementGuidelines for"/>
 <result pre="Chin Antituberculous Assoc.2003;25:232-234. 84.JonklaasJ, BiancoAC, BauerAJ, et al.; collab: American" exact="Thyroid" post="Association Task Force on Thyroid Hormone ReplacementGuidelines for the"/>
 <result pre="BauerAJ, et al.; collab: American Thyroid Association Task Force on" exact="Thyroid" post="Hormone ReplacementGuidelines for the treatment of hypothyroidism: prepared by"/>
 <result pre="Hormone ReplacementGuidelines for the treatment of hypothyroidism: prepared by the" exact="American" post="Thyroid Association task force on thyroid hormone replacement. Thyroid.2014;24(12):1670-1751.25266247"/>
 <result pre="ReplacementGuidelines for the treatment of hypothyroidism: prepared by the American" exact="Thyroid" post="Association task force on thyroid hormone replacement. Thyroid.2014;24(12):1670-1751.25266247 85.WeiL,"/>
 <result pre="85.WeiL, SunS, XuCH, et al.Pathology of the thyroid in severe" exact="acute" post="respiratory syndrome. Hum Pathol.2007;38(1):95-102.16996569 86.SunS, WeiL, ZhangJ, XuY, HeFJ,"/>
 <result pre="SunS, XuCH, et al.Pathology of the thyroid in severe acute" exact="respiratory" post="syndrome. Hum Pathol.2007;38(1):95-102.16996569 86.SunS, WeiL, ZhangJ, XuY, HeFJ, GuJ[Pathology"/>
 <result pre="ZhangJ, XuY, HeFJ, GuJ[Pathology and immunohistochemistry of thyroid in severe" exact="acute" post="respiratory syndrome]. Zhonghua Yi Xue Za Zhi.2005;85(10):667-670.15932728 87.DingY, HeL,"/>
 <result pre="XuY, HeFJ, GuJ[Pathology and immunohistochemistry of thyroid in severe acute" exact="respiratory" post="syndrome]. Zhonghua Yi Xue Za Zhi.2005;85(10):667-670.15932728 87.DingY, HeL, ZhangQ,"/>
 <result pre="Za Zhi.2005;85(10):667-670.15932728 87.DingY, HeL, ZhangQ, et al.Organ distribution of severe" exact="acute" post="respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients:"/>
 <result pre="Zhi.2005;85(10):667-670.15932728 87.DingY, HeL, ZhangQ, et al.Organ distribution of severe acute" exact="respiratory" post="syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications"/>
 <result pre="87.DingY, HeL, ZhangQ, et al.Organ distribution of severe acute respiratory" exact="syndrome" post="(SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for"/>
 <result pre="transmission pathways. J Pathol.2004;203(2):622-630.15141376 88.BrancatellaA, RicciD, ViolaN, SgrÃ²D, SantiniF, LatrofaF.Subacute" exact="thyroiditis" post="after SARS-CoV-2 infection. J Clin Endocrinol Metab. 105(7):dgaa276. doi:10.1210/clinem/dgaa276"/>
 <result pre="18, 2020. 90.RomanelliA, MascoloSImmunosuppression drug-related and clinical manifestation of coronavirus" exact="disease" post="2019: a therapeutical hypothesis. Am J Transplant. 2020;20(7):1947-1948.32243698 91.FangHJ,"/>
 <result pre="of SARS coronavirus to its receptor damages islets and causes" exact="acute" post="diabetes. Acta Diabetol.2010;47(3):193-199.19333547 93.LiuF, LongX, ZouW, et al.Highly ACE2"/>
 <result pre="2017;18(3). doi:10.3390/ijms18030563. 95.LangZ, ZhangL, ZhangS, et al.Pathological study on severe" exact="acute" post="respiratory syndrome. Chin Med J (Engl).2003;116(7):976-980.12890365 96.GuJ, GongE, ZhangB,"/>
 <result pre="doi:10.3390/ijms18030563. 95.LangZ, ZhangL, ZhangS, et al.Pathological study on severe acute" exact="respiratory" post="syndrome. Chin Med J (Engl).2003;116(7):976-980.12890365 96.GuJ, GongE, ZhangB, et"/>
 <result pre="Chin Med J (Engl).2003;116(7):976-980.12890365 96.GuJ, GongE, ZhangB, et al.Multiple organ" exact="infection" post="and the pathogenesis of SARS. J Exp Med.2005;202(3):415-424.16043521 97.ShiX,"/>
 <result pre="of SARS. J Exp Med.2005;202(3):415-424.16043521 97.ShiX, GongE, GaoD, et al.Severe" exact="acute" post="respiratory syndrome associated coronavirus is detected in intestinal tissues"/>
 <result pre="SARS. J Exp Med.2005;202(3):415-424.16043521 97.ShiX, GongE, GaoD, et al.Severe acute" exact="respiratory" post="syndrome associated coronavirus is detected in intestinal tissues of"/>
 <result pre="J Exp Med.2005;202(3):415-424.16043521 97.ShiX, GongE, GaoD, et al.Severe acute respiratory" exact="syndrome" post="associated coronavirus is detected in intestinal tissues of fatal"/>
 <result pre="Med Virol. 2020;92(7):770-775.32293710 102.The Clinical Features of SARS Patients with" exact="Diabetes" post="or Secondary Hyperglycemia. American Diabetes Associationhttps://professional.diabetes.org/abstract/clinical-features-sars-patients-diabetes-or-secondary-hyperglycemia. Accessed April 18,"/>
 <result pre="2020;92(7):770-775.32293710 102.The Clinical Features of SARS Patients with Diabetes or" exact="Secondary" post="Hyperglycemia. American Diabetes Associationhttps://professional.diabetes.org/abstract/clinical-features-sars-patients-diabetes-or-secondary-hyperglycemia. Accessed April 18, 2020. 103.KatulandaP,"/>
 <result pre="Clinical Features of SARS Patients with Diabetes or Secondary Hyperglycemia." exact="American" post="Diabetes Associationhttps://professional.diabetes.org/abstract/clinical-features-sars-patients-diabetes-or-secondary-hyperglycemia. Accessed April 18, 2020. 103.KatulandaP, DissanayakeHA, RanathungaI,"/>
 <result pre="Features of SARS Patients with Diabetes or Secondary Hyperglycemia. American" exact="Diabetes" post="Associationhttps://professional.diabetes.org/abstract/clinical-features-sars-patients-diabetes-or-secondary-hyperglycemia. Accessed April 18, 2020. 103.KatulandaP, DissanayakeHA, RanathungaI, et"/>
 <result pre="104.BornsteinSR, RubinoF, KhuntiK, et al.Practical recommendations for the management of" exact="diabetes" post="in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550.32334646 105.DruckerDJCoronavirus"/>
 <result pre="for the management of diabetes in patients with COVID-19. Lancet" exact="Diabetes" post="Endocrinol. 2020;8(6):546-550.32334646 105.DruckerDJCoronavirus infections and type 2 diabetesâ€&quot;shared pathways"/>
 <result pre="diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550.32334646 105.DruckerDJCoronavirus" exact="infections" post="and type 2 diabetesâ€&quot;shared pathways with therapeutic implications. Endocr"/>
 <result pre="patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550.32334646 105.DruckerDJCoronavirus infections and" exact="type 2" post="diabetesâ€&quot;shared pathways with therapeutic implications. Endocr Rev. 2020;41(3). doi:10.1210/endrev/bnaa011"/>
 <result pre="Rev. 2020;41(3). doi:10.1210/endrev/bnaa011 106.FadiniGP, MorieriML, LongatoE, AvogaroAPrevalence and impact of" exact="diabetes" post="among people infected with SARS-CoV-2. J Endocrinol Invest.2020;43(6):867-869.32222956 107.ChenC,"/>
 <result pre="myocardial injury in patients with COVID-19 and association between concomitant" exact="cardiovascular" post="diseases and severity of COVID-19]. Zhonghua Xin Xue Guan"/>
 <result pre="Za Zhi.2020;48(0):E008.32141280 108.DietzW, Santos-BurgoaCObesity and its implications for COVID-19 mortality." exact="Obesity" post="(Silver Spring).2020;28(6):1005.32237206 109.ZhuL, SheZG, ChengX, et al.Association of blood"/>
 <result pre="glucose control and outcomes in patients with COVID-19 and pre-existing" exact="type 2" post="diabetes. Cell Metab.2020;31(6):1068-1077.e3.32369736 110.HoflandJ, KaltsasG, de HerderWWAdvances in the"/>
 <result pre="GrossmanAB, ThakkerRVEndocrinology in the time of COVID-19: Management of neuroendocrine" exact="neoplasms" post="(NENs). Eur J Endocrinol.2020:1-24. doi:10.1530/EJE-20-0424 112.ZhouY, FreyTK, YangJJViral calciomics:"/>
 <result pre="Altern Med. 2018;2018. doi:10.1155/2018/5813095 117.DancerRC, ParekhD, LaxS, et al.Vitamin D" exact="deficiency" post="contributes directly to the acute respiratory distress syndrome (ARDS)."/>
 <result pre="ParekhD, LaxS, et al.Vitamin D deficiency contributes directly to the" exact="acute" post="respiratory distress syndrome (ARDS). Thorax.2015;70(7):617-624.25903964 118.CoussensAK, WilkinsonRJ, NikolayevskyyV, et"/>
 <result pre="LaxS, et al.Vitamin D deficiency contributes directly to the acute" exact="respiratory" post="distress syndrome (ARDS). Thorax.2015;70(7):617-624.25903964 118.CoussensAK, WilkinsonRJ, NikolayevskyyV, et al.Ethnic"/>
 <result pre="al.Vitamin D deficiency contributes directly to the acute respiratory distress" exact="syndrome" post="(ARDS). Thorax.2015;70(7):617-624.25903964 118.CoussensAK, WilkinsonRJ, NikolayevskyyV, et al.Ethnic variation in"/>
 <result pre="LamCW, WuAK, et al.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndrome. Clin Exp Immunol.2004;136(1):95-103.15030519 120.MahallawiWH, KhabourOF, ZhangQ, MakhdoumHM,"/>
 <result pre="WuAK, et al.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndrome. Clin Exp Immunol.2004;136(1):95-103.15030519 120.MahallawiWH, KhabourOF, ZhangQ, MakhdoumHM, SulimanBAMERS-CoV"/>
 <result pre="respiratory syndrome. Clin Exp Immunol.2004;136(1):95-103.15030519 120.MahallawiWH, KhabourOF, ZhangQ, MakhdoumHM, SulimanBAMERS-CoV" exact="infection" post="in humans is associated with a pro-inflammatory Th1 and"/>
 <result pre="of single-dose injection of vitamin D on immune cytokines in" exact="ulcerative colitis" post="patients: a randomized placebo-controlled trial. Apmis.2019;127(10):681-687.31274211 122.CantornaMT, SnyderL, LinYD,"/>
 <result pre="single-dose injection of vitamin D on immune cytokines in ulcerative" exact="colitis" post="patients: a randomized placebo-controlled trial. Apmis.2019;127(10):681-687.31274211 122.CantornaMT, SnyderL, LinYD,"/>
 <result pre="Microbes Infect.2020;9(1):601-604.32178593 124.KomolmitP, CharoensukK, ThanapiromK, et al.Correction of vitamin D" exact="deficiency" post="facilitated suppression of IP-10 and DPP IV levels in"/>
 <result pre="suppression of IP-10 and DPP IV levels in patients with" exact="chronic hepatitis" post="C: a randomised double-blinded, placebo-control trial. Plos One.2017;12(4):e0174608.28376103 125.ZhangH,"/>
 <result pre="of IP-10 and DPP IV levels in patients with chronic" exact="hepatitis" post="C: a randomised double-blinded, placebo-control trial. Plos One.2017;12(4):e0174608.28376103 125.ZhangH,"/>
 <result pre="Med.2020;46(4):586-590.32125455 126.XuJ, YangJ, ChenJ, LuoQ, ZhangQ, ZhangHVitamin D alleviates lipopolysaccharideâ€‘induced" exact="acute" post="lung injury via regulation of the reninâ€‘angiotensin system. Mol"/>
 <result pre="et al.Trends in the incidence of testing for Vitamin D" exact="deficiency" post="in primary care in the UK: a retrospective analysis"/>
 <result pre="in the incidence of testing for Vitamin D deficiency in" exact="primary" post="care in the UK: a retrospective analysis of the"/>
 <result pre="vitamin D supplementation could reduce risk of influenza and COVID-19" exact="infections" post="and deaths. Nutrients. 2020;12(4):988. doi:10.3390/nu12040988 130.Gruber-BzuraBMVitamin D and influenzaâ€&quot;prevention"/>
 <result pre="doi:10.3390/ijms19082419 131.MartineauAR, JolliffeDA, HooperRL, et al.Vitamin D supplementation to prevent" exact="acute" post="respiratory tract infections: systematic review and meta-analysis of individual"/>
 <result pre="131.MartineauAR, JolliffeDA, HooperRL, et al.Vitamin D supplementation to prevent acute" exact="respiratory" post="tract infections: systematic review and meta-analysis of individual participant"/>
 <result pre="individual participant data. Bmj.2017;356:i6583.28202713 132.AmreinK, ScherklM, HoffmannM, et al.Vitamin D" exact="deficiency" post="2.0: an update on the current status worldwide. Eur"/>
 <result pre="enzyme. FEBS Lett. 2002;532(1â€&quot;2):107-110. doi:10.1016/s0014-5793(02)03640-212459472 138.WangZ, XuXscRNA-seq profiling of human" exact="testes" post="reveals the presence of the ACE2 receptor, a target"/>
 <result pre="the presence of the ACE2 receptor, a target for SARS-CoV-2" exact="infection" post="in spermatogonia, Leydig and Sertoli cells. Cells. 2020;9(4). doi:10.3390/cells9040920"/>
 <result pre="doi:10.3390/cells9040920 139.XuJ, QiL, ChiX, et al.Orchitis: a complication of severe" exact="acute" post="respiratory syndrome (SARS). Biol Reprod.2006;74(2):410-416.16237152"/>
 <result pre="139.XuJ, QiL, ChiX, et al.Orchitis: a complication of severe acute" exact="respiratory" post="syndrome (SARS). Biol Reprod.2006;74(2):410-416.16237152"/>
 <result pre="QiL, ChiX, et al.Orchitis: a complication of severe acute respiratory" exact="syndrome" post="(SARS). Biol Reprod.2006;74(2):410-416.16237152"/>
</results>
